|
|
| |
| Projects In Knowledge is pleased to present The Advanced Certificate Program: Breast Cancer Management comprised of Curricula I and II. |
|
Curriculum I courses present a basic overview of management strategies for optimal personalized care of breast cancer patients.
Curriculum II presents more advanced courses that build on new scientific developments and the topics covered in Curriculum I.
|
| Featuring the very latest state-of-the-science information about breast cancer diagnosis, breast cancer treatment, and breast cancer disease management, this free online curriculum offers CME, CE, and CPE credit to oncologists and other clinicians who care for patients with breast cancer. |
| The curriculum courses are updated continuously throughout the year. |
| The Advanced Certificate Program: Breast Cancer Management is building a community of experts to help you provide your patients with the best treatment outcome possible. |
|
|
|
| |
|
|
Chair: |
|
|
Harold J. Burstein, MD, PhD
Associate Professor of
Medicine
Dana-Farber Cancer
Institute
Harvard Medical School
Boston, Massachusetts
|
| |
|
The robust, clinically focused, CME/CE curriculum has been designed to provide in-depth coverage of
- Breast cancer pathophysiology
- Cytokines
- Hormones
- Growth factors
- Oncogenes
- Mutations
- Dysregulation of cell signaling
- Vascular endothelial growth factors (VEGF)
- Epidermal growth factors (EGF)
- Nuclear transcription factors (NTF)
- Platelet derived growth factor (PDGF)
- Tyrosine kinase (TK)
- Mammalian target of rapamycin (mTOR)
- Apoptosis
- Cell proliferation
- Early- and late-stage breast cancer
- Premenopausal and postmenopausal
- Metastatic breast cancer
- Tumor node metastasis (TNM)
- Estrogen-receptor genes in metastases to bone
- Risk factors and genetics
- Molecular screening
- Biomarkers from DNA, RNA, and protein
- Genetic mutations
- Genetic expression
- Use of Oncotype DX to select candidates for adjuvant chemotherapy
- Biologic subsets as predictors of response
- Evidence-based treatment guidelines
- Monoclonal antibodies and tyrosine kinase inhibitors (TKI)
- Cytotoxic chemotherapy
- Third line for metastatic breast cancer
- Adjuvant therapy in early-stage breast cancer
- Adjuvant therapy in triple-negative breast cancer
- Alone and in combination with targeted agents for metastatic breast cancer
- Targeted agents—systemic therapies
- Current and emerging research data
- HER2+ and HER2-
- Antiangiogenic
- Bevacizumab
- Cetuximab
- Erlotinib
- Imatinib
- Trastuzumab-DM1 (TDM1)
- PARP inhibitors
- Endocrine/hormone therapy
- Hormone agonists as adjuvant treatment
- Premenopausal patients with hormone-receptor-positive breast cancer
- Endocrine therapy
- Postmenopausal patients with estrogen-receptor-positive breast cancer
- Use in advanced breast cancer
- Tolerability of therapy and adherence
- Neoadjuvant therapy
- Dose-dense therapy
- Preoperatively
|
Learning Objectives:
- Apply evidence-based guidelines to determine optimal treatment interventions for patients with or at risk for developing breast cancer through an understanding of the epidemiology, risk factors, and disease burden imposed by breast cancer, including genetic factors, dietary modification, morbidity, and mortality.
- Assess the role of genetic and other markers in determining optimal treatment selection in breast cancer patients, and in evaluating treatment response to therapy to improve patient outcomes.
- Evaluate the appropriate use of chemotherapy, hormone therapy, and targeted therapy agents in treatment strategies for breast cancer patients that improve outcomes through knowledge of their efficacy and safety.
- Assess the challenges in promoting treatment compliance, including long-term compliance, and address the long-term consequences of treatment.
|
|
Projects In Knowledge Poster Presented
at 2009 ASCO Breast Cancer Symposium
Harold J. Burstein, MD, PhD, and Projects In Knowledge collaborated on a poster that reported proprietary survey findings that identified knowledge gaps and learning opportunities for clinicians who treat patients with breast cancer. The poster was on display at the 2009 ASCO Breast Cancer Symposium, General Poster Session B, held in San Francisco, CA.
To access the poster PDF, click on the following link:
www.projectsinknowledge.com/2009ASCO
|
| Treatment Strategies Discussed |
- Early-stage breast cancer management
- Chemotherapy
- Endocrine/hormone therapy
- Targeted therapy
- Bisphosphonates
- Metastatic breast cancer management
- Chemotherapy
- Hormone therapy
- Targeted therapies
- Anti-HER2 agents
- Antiangiogenic agents
- PARP inhibitors
- Bone metastasis management
- Neoadjuvant therapy
|
| Covered Topics Include |
- Hereditary breast cancer
- Adjuvant treatment for premenopausal and postmenopausal women
- Hormone-receptor-positive breast cancer
- Primary endocrine therapy
- Estrogen-receptor-positive breast cancer
- Third-line chemotherapy in metastatic breast cancer
- Biomolecular predictors
- Adjuvant systemic therapy in early-stage breast cancer
- Estrogen-responsive genes in metastases to the bone
- Cancer risk assessment with biomarkers
- Postoperative treatment with targeted therapies for patients with HER2+ & HER2-
- Dose-dense adjuvant therapy
- Hormonal therapy for advanced breast cancer
- Neoadjuvant systemic therapy
- Molecular screening for breast cancer
- 21-gene recurrence score prognostic assay
- Small (subcentimeter) HER2+ breast cancer
- Triple-negative breast cancer
- Endocrine-sensitive, HER2- breast cancer in postmenopausal women
|
|
Breast Cancer News powered by
 |
|
|
|
|
|
|
About the Program
